

Appendix File 4.

The pre-defined intervention-related adverse events are:

Endocrine system: impaired glucose tolerance, steroid diabetes mellitus (or exacerbating diabetes that has existed), hyperlipidemia, hypogonadism (seen as menstrual disturbances in women), growth retardation, adrenal insufficiency;

Digestive system: induce or aggravate gastroduodenal disease (gastroduodenal ulcer or gastrointestinal bleeding);

Nervous system: psychiatric symptoms, including anxiety, excitement, euphoria, insomnia, teleangiectasis, increased sweating, psychiatric disorders and epileptic seizures, hallucinations, mania, personality disorders;

Blood system: purpura, leukocytosis, leukopenia, lymphopenia, thrombocytosis, hemorrhagic tendency;

Cardiovascular system: hypertension, congestive heart failure, atherosclerosis and thrombus formation;

Orthopaedic Diseases: osteonecrosis of the femoral head, osteoporosis, spontaneous fracture;

Ophthalmic disease: glucocorticoid induced glaucoma and cataract;

Infection: induce or aggravate bacterial, viral or fungal infection;

Urinary system: urolithiasis;

Skin and wound healing: striae, delayed wound healing;

Other diseases: myopathy, myasthenia, amyotrophy, hypokalemia, sodium retention, edema, allergic reactions.